VIVLODEX® gives patients with osteoarthritis pain a low-dose NSAID treatment option

To find out more about nonsteroidal anti-inflammatory drugs (NSAIDs)—and to learn how Iroko Pharmaceuticals, LLC has used SoluMatrix Fine Particle Technology to create a low-dose NSAID treatment option for managing osteoarthritis pain—click these links:

VIVLODEX: The lowest FDA-approved dose of meloxicam available (5 mg)

VIVLODEX is the first low-dose SoluMatrix® meloxicam for osteoarthritis pain approved by the US Food and Drug Administration (FDA).

VIVLODEX: A low-dose SoluMatrix® NSAID for management of osteoarthritis pain

Iroko created VIVLODEX with osteoarthritis patients in mind:

  • VIVLODEX is the first low-dose SoluMatrix® meloxicam
  • Meloxicam is a trusted NSAID that is used to manage pain caused by osteoarthritis
  • Low-dose SoluMatrix® NSAIDs were developed by Iroko to align with recommendations from FDA, medical organizations, and advocacy groups: Use the lowest NSAID dose possible for the shortest time needed for your treatment

In addition to being the first low-dose SoluMatrix® meloxicam available, clinical studies demonstrated that VIVLODEX:

  • Helped patients experience significant improvements in osteoarthritis pain compared with patients who took placebo
  • Was generally well tolerated
VIVLODEX is FDA approved at low 5-mg and 10-mg doses administered once daily for management of osteoarthritis pain.

VIVLODEX was developed using SoluMatrix Fine Particle Technology, a proprietary technology used to create NSAID drug particles that are approximately 10 to 20 times smaller than their original size.

  • Helps drugs dissolve quickly so they can be rapidly absorbed in the body
Particle Chart

Original NSAID particles

SoluMatrix® NSAID particles

See how SoluMatrix Fine Particle Technology reduces the size of drug particles!

Eligible* patients
pay as little as
$10

*Terms and Conditions may apply.

Looking for a low-dose NSAID option to manage OA pain?

Ask Your Doctor About VIVLODEX®

NSAID use and FDA: Warnings and recommendations

Over the past decade, FDA has monitored and evaluated the safety of NSAIDs

  • icon

    In 2005, FDA required manufacturers of all prescription NSAIDs to include a Boxed Warning and a Medication Guide:

    • The Boxed Warning highlighted the potential for increased risk of serious cardiovascular (CV) events with these drugs and the well-described, serious, and potentially life-threatening gastrointestinal (GI) bleeding associated with their use
    • FDA recommended using the lowest NSAID dose possible for the shortest time needed for your treatment
  • icon

    In July 2015, FDA strengthened the Boxed Warning to include statements that non-aspirin NSAIDs increase the chance of a heart attack or stroke. FDA is requiring all manufacturers of all prescription NSAID pain relievers—including medications like ibuprofen (Motrin®), celecoxib (Celebrex®), and naproxen (Naprosyn®)—to include updated safety language within their product labels.

  • icon
  • icon

    Starting in May 2016, prescription NSAID labels now reflect the following information:

    • The risk of heart attack or stroke can occur as early as the first weeks of using an NSAID
      • The risk may increase with longer use of the NSAID
    • The risk appears greater at higher doses
    • NSAIDs can increase the risk of heart attack or stroke in patients with or without heart disease or risk factors for heart disease

    FDA recommends that NSAIDs be used at the lowest possible dose for the shortest time needed.

Other healthcare-related organizations support FDA recommendations

In addition to FDA, professional medical organizations and patient advocacy groups also recognize the importance of using the lowest effective NSAID dosage for the shortest duration:

  • American Heart Association
  • American College of Cardiology
  • National Kidney Foundation
  • American College of Rheumatology

Potential risks associated with NSAID use

The higher the NSAID dose, the higher the risk of certain serious side effects

Risk of heart problems

Increased NSAID doses may increase:

The risk of heart attack or stroke in people with or without heart disease or risk factors for heart disease

Risk of stomach and GI problems

Increased NSAID doses may increase:

The risk of bleeding, ulcers, and tears (perforations) of the esophagus (the tube leading from the mouth to the stomach), stomach, and intestines

Risk of kidney problems

Increased NSAID doses may increase:

The risk of kidney problems, including kidney failure

VIVLODEX® matters because:

Nearly half of all patients treated for osteoarthritis pain are treated with an NSAID

Meloxicam is a trusted NSAID physicians commonly use to help patients with osteoarthritis pain

While NSAIDs including meloxicam can help manage pain and reduce inflammation, studies have shown they can potentially lead to certain serious side effects involving the heart, stomach, and kidneys

The risk of certain serious side effects increases with increasing doses and longer use of NSAIDs

FDA recommends that NSAIDs be used:

  • Exactly as your doctor prescribes them
  • At the lowest dose possible for your treatment
  • For the shortest time needed

VIVLODEX (5 mg) provides the lowest available dose of meloxicam.

Looking for a low-dose NSAID option to manage OA pain?

Ask Your Doctor About VIVLODEX®

Eligible* patients pay as little as $10.

*Terms and Conditions may apply.

Get Your Savings Card